SCHEMBL10058970

SCHEMBL10058970

CCCCCCCc1nnc(-c2ccc(-c3nnc(CCCCCCC)s3)cc2)s1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
KDM4E B2RXH2 3/20 0.59
ALDH1A1 P00352 3/20 0.56
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.45
DNMT1 P26358 1/20 0.45
NPSR1 Q6W5P4 1/20 0.42
CSNK2A2 P19784 1/20 0.41
CSNK2A1 P68400 1/20 0.41
AKT1 P31749 1/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
USP2 O75604 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HSD11B1 P28845 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10058957 1.00 RAB9A (0.59) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL10058949 1.00 RAB9A (0.59) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL10058950 1.00 RAB9A (0.59) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL10058952 1.00 RAB9A (0.59) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL10058947 0.98 RAB9A (0.61) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL15164266 0.95 KDM4E (0.68) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL15164267 0.94 RAB9A (0.54) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL9702885 0.94 KDM4E (0.66) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL9704102 0.92 RAB9A (0.60) RAB9AKDM4EALDH1A1MAPTLMNA
SCHEMBL8742458 0.92 PTGS2 (0.53) RAB9AKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8480926-B2 Liquid-crystalline compound and organic semiconductor device containing the compound JNC CORPORATION (JP) 2013-07-09 US disclosed
US-8480926-B2 Liquid-crystalline compound and organic semiconductor device containing the compound JNC CORPORATION (JP) 2013-07-09 US disclosed
US-20120007062-A1 NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND JNC CORPORATION (JP) 2012-01-12 US disclosed
US-20120007062-A1 NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND JNC CORPORATION (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120007062-A1 NOVEL LIQUID-CRYSTALLINE COMPOUND AND ORGANIC SEMICONDUCTOR DEVICE CONTAINING THE COMPOUND ARNT, SLCO2A1, CRY2 RAB9A 1757/4885KDM4E 3424/4885ALDH1A1 1916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.